Literature DB >> 12362414

Phenotypic variability among first-degree relatives with carnitine palmitoyltransferase II deficiency.

Georgirene D Vladutiu1, Michael J Bennett, Nadine M Fisher, David Smail, Richard Boriack, John Leddy, David R Pendergast.   

Abstract

Carnitine palmitoyltransferase (CPT) II deficiency disorders are clinically very variable. To examine the cause(s) of variable symptoms in first-degree relatives with CPT II deficiency, four sisters with various combinations of mutations and polymorphisms in the CPT2 gene were studied, together with 20 sedentary and 24 trained healthy female subjects. One sister, whose symptoms began at age 7 years, was more severely affected than her older sister, whose symptoms began at age 16 years; both were compound heterozygotes for the common S113L mutation and Q413fs, and for the common CPT2 polymorphisms, V3681 and M647V. A third sister became hypoglycemic with fasting, was heterozygous for the S113L mutation, and homozygous for the polymorphism variants. The fourth sister was asymptomatic, heterozygous for the Q413fs mutation, and homozygous for the normal polymorphisms. Residual CPT II activity in skeletal muscle and cultured skin fibroblasts from the two myopathic sisters, and palmitate oxidation in fibrobasts, were abnormally low; cellular and total body fat oxidation were also diminished. Muscle function and fat oxidation were nomal at rest, but a switch to carbohydrate utilization occurred at lower exercise intensities than in sedentary and trained individuals, respectively. Reliance on carbohydrates during stress and hormonal alterations may explain, in part, the variance in ages of onset and serverity of symptoms in myopathic patients. Copyright 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 492-498, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362414     DOI: 10.1002/mus.10217

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

Review 1.  Influence of exercise on nutritional requirements.

Authors:  D R Pendergast; K Meksawan; A Limprasertkul; N M Fisher
Journal:  Eur J Appl Physiol       Date:  2010-11-16       Impact factor: 3.078

2.  Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation.

Authors:  N M Fisher; K Meksawan; A Limprasertkul; P J Isackson; D R Pendergast; G D Vladutiu
Journal:  J Inherit Metab Dis       Date:  2007-04-05       Impact factor: 4.982

Review 3.  Genomics and genetics in the biology of adaptation to exercise.

Authors:  Claude Bouchard; Tuomo Rankinen; James A Timmons
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

4.  The distribution of white blood cell fat oxidation in health and disease.

Authors:  D R Pendergast; N M Fisher; K Meksawan; M Doubrava; G D Vladutiu
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency.

Authors:  S E Olpin; A Afifi; S Clark; N J Manning; J R Bonham; A Dalton; J V Leonard; J M Land; B S Andresen; A A Morris; F Muntoni; D Turnbull; M Pourfarzam; S Rahman; R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 6.  Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach.

Authors:  Pushpa Raj Joshi; Stephan Zierz
Journal:  Molecules       Date:  2020-04-13       Impact factor: 4.411

Review 7.  Carnitine Inborn Errors of Metabolism.

Authors:  Mohammed Almannai; Majid Alfadhel; Ayman W El-Hattab
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

Review 8.  Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability.

Authors:  Simon E Olpin
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.